Compare ALTI & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALTI | GLSI |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | 490 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.6M | 372.0M |
| IPO Year | 2021 | 2020 |
| Metric | ALTI | GLSI |
|---|---|---|
| Price | $3.79 | $26.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 143.9K | 131.8K |
| Earning Date | 05-11-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $254,956,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $10.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 23.21 | N/A |
| 52 Week Low | $2.96 | $7.78 |
| 52 Week High | $5.45 | $34.10 |
| Indicator | ALTI | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 53.00 |
| Support Level | $3.76 | $21.20 |
| Resistance Level | $3.92 | $30.02 |
| Average True Range (ATR) | 0.22 | 1.87 |
| MACD | 0.06 | 0.38 |
| Stochastic Oscillator | 70.67 | 71.65 |
AlTi Global Inc is a wealth and investment partner to families, foundations, and institutions, helping clients activate capital, bring structure to complexity, and plan across borders and generations. The company combines the breadth of an international firm with the service offering of a family office to deliver solutions for wealth and capital. It provides services including discretionary and non-discretionary investment advisory, estate and wealth planning, trust and fiduciary, governance, philanthropy, and family office services, along with access to alternative investment opportunities. The company generates revenue from management, advisory, trustee, or administration fees, performance or incentive fees, distributions from investments, and other income or fees.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.